ASX Cannabis Stocks: Starpharma Up 10% on Study Results; Mach7 Announces $3.7M Deal

2 min read | July 24, 2023 07:08 AM AEST | By Team Kalkine Media

Google News:

ASX Cannabis Stocks: Starpharma Up 10% on Study Results; Mach7 Announces $3.7M Deal — Image source: shutterstock.com

Recent News

Has Excelsior HPAL Changed Nickel Industries’ Battery Metals Story?

Can Centuria Industrial REIT’s Data Centre Push Change the Growth Stor...

Is Dyno Nobel’s Dividend Focus Hiding a Bigger Cash Flow Story?

These ASX Penny Stocks Are Standing Out Below the Radar

Make Kalkine Media
My Trusted Source

ASX cannabis stocks are making waves in the market, with notable players like Starpharma and Mach7 gaining attention for their recent developments.

1. Starpharma (ASX:SPL) - Up 10% on Study Results:

Starpharma, a leading biopharmaceutical company, witnessed a 10% surge in its share price following the announcement of positive study results. The ASX SPL focuses on the development of innovative pharmaceutical products, including cannabis-related treatments.

The study results demonstrated the efficacy and potential of Starpharma's cannabis-based products, creating excitement among investors and industry experts. The positive outcome positions the company as a promising player in the cannabis sector, drawing attention from those seeking opportunities in the rapidly growing cannabis market.

2. Mach7 Technologies (ASX:M7T) - Announces $3.7M Deal:

Mach7 Technologies, a cutting-edge healthcare technology company, recently revealed a significant deal worth $3.7 million. The ASX M7T is actively involved in the integration and enhancement of medical imaging technologies, including applications in the cannabis industry.

The deal showcases the growing demand for innovative technologies in the cannabis space, and Mach7's involvement further reinforces its presence in the cannabis market. The announcement has piqued the interest of investors looking to capitalize on the expanding opportunities in the cannabis sector.

As the cannabis industry continues to gain traction and acceptance globally, ASX cannabis stocks are becoming increasingly attractive for investors seeking exposure to this high-potential market. However, it's crucial to note that investing in cannabis stocks can be inherently risky due to the regulatory landscape and evolving nature of the industry.

Investors interested in ASX cannabis stocks should conduct thorough research and consider factors such as the companies' financial health, product pipeline, regulatory compliance, and overall market sentiment. Diversifying one's investment portfolio and consulting with a qualified financial advisor can also help mitigate risks associated with investing in the cannabis sector.

Overall, the performance and developments of ASX cannabis stocks like Starpharma and Mach7 exemplify the growing interest and potential within the cannabis industry. Investors looking to explore opportunities in this space should remain vigilant, staying informed about industry trends and developments to make informed investment decisions.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.